- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01058785
Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer
Phase II Study of Lucanix™ (TGF-beta2 Antisense Gene Modified Allogeneic Tumor Cell Vaccine) in Patients With Stages II-IV Non-Small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a 2-stage, open-label, three-arm, Phase II study. It is designed to evaluate the efficacy of immunization with increasing doses of an allogeneic tumor cell vaccine, Lucanix™, in patients with non-curable NSCLC. Patients will be followed for clinical response, immunogenicity and safety.
Eligible patients will receive 4 monthly intradermal injections with a cell cocktail comprised of equal numbers of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients will be randomized to one of the three study cohorts. Patients will receive 12,500,000, 25,000,000, 50,000,000 gene modified cells respectively. Treated patients will be evaluated four months after they enter therapy. Patients that respond to therapy will receive an additional four to twelve injections to evaluate whether their response to therapy can be amplified. Response, time to tumor progression, and tumor free survival will be monitored in patients and compared with historical controls and patients receiving other forms of therapy. Patients will be monitored and evaluated according to standard evaluation criteria of no response, stable disease, partial response and complete response.
PRIMARY OBJECTIVE
-Evaluate the ability of increasing doses of Lucanix™, a gene-modified tumor cell vaccine, to induce tumor response in patients with non-curable NSCLC
SECONDARY OBJECTIVES
- Evaluate the ability of the Lucanix™ vaccination regimen to induce an immune response (cellular and humoral)
- Estimate the response duration for the Lucanix™ regimen
- Evaluate the effects of repeated inoculations on immune infiltrates
- Evaluate the safety of the Lucanix™ regimen
INCLUSION CRITERIA
- Signed informed consent
- 18 years
- Histologically confirmed non-curable NSCLC with an estimated total tumor burden volume of less than or equal to 125 cc, confirmed to be stage II, III, or IV.
- Must have completed or refused conventional therapy
- Performance status (ECOG) less than 2.
- Absolute granulocyte count greater than or equal to 1,500/mm3
- Platelet count greater than or equal to 100,000/mm3
- Total Bilirubin less then or equal to 2 mg/dL
- AST and ALT less than or equal to 2x Upper Limit of Normal
- Creatinine less than or equal to 1.5 mg/dL
EXCLUSION CRITERIA
- Concurrent systemic steroids greater than 2 mg prednisone/day
- Prior splenectomy
- Any surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy or immunotherapy less than 4 weeks of study entry
- Brain metastases or meningeal lymphomatosis unless treated and stable for greater than or equal to 2 months
- Known HIV positive
- Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions which, in the opinion of the investigator would compromise protocol objectives.
- Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for greater than or equal to 2 years
- Treatment with an investigational drug within 30 days prior to study entry
- History of psychiatric disorder that would impede adherence to protocol
- Pregnant or nursing women or refusal to practice contraception if of reproductive potential
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Newport Beach, California, United States, 92658
- Hoag Cancer Center
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD, and Janet Burroff MD APM
-
-
Texas
-
Dallas, Texas, United States, 75201
- Mary Crowley Medical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- 18 years
- Histologically confirmed non-curable NSCLC with an estimated total tumor burden volume of less than or equal to 125 cc, confirmed to be stage II, III, or IV.
- Must have completed or refused conventional therapy
- Performance status (ECOG) less than 2.
- Absolute granulocyte count greater than or equal to 1,500/mm3
- Platelet count greater than or equal to 100,000/mm3
- Total Bilirubin less than or equal to 2 mg/dL
- AST and ALT less than or equal to 2x Upper Limit of Normal
- Creatinine less than or equal to 1.5 mg/Dl
Exclusion Criteria:
- Concurrent systemic steroids greater than 2 mg prednisone/day
- Prior splenectomy
- Any surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy or immunotherapy less than 4 weeks of study entry
- Brain metastases or meningeal lymphomatosis unless treated and stable for ≥ 2 months
- Known HIV positive
- Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions which, in the opinion of the investigator would compromise protocol objectives.
- Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for greater than or equal to 2 years
- Treatment with an investigational drug within 30 days prior to study entry
- History of psychiatric disorder that would impede adherence to protocol
- Pregnant or nursing women or refusal to practice contraception if of reproductive potential
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lucanix
Patients will receive injections of Lucanix for each dose cohort.
|
Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines.
Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the ability of increasing doses of Lucanix™, a gene-modified tumor cell vaccine, to induce tumor response in patients with non-curable NSCLC
Time Frame: Week 16, quarterly during treatment and first year of post-intervention follow-up
|
Week 16, quarterly during treatment and first year of post-intervention follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Habib Fakhrai, PhD, NovaRx Corporation
Publications and helpful links
General Publications
- Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Shawler DL. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. 2006 Dec;13(12):1052-60. doi: 10.1038/sj.cgt.7700975. Epub 2006 Jul 7.
- Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006 Oct 10;24(29):4721-30. doi: 10.1200/JCO.2005.05.5335. Epub 2006 Sep 11.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BB-IND 8868
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Bronchogenic
-
University College London HospitalsThe Whittington Hospital NHS Trust; Barnet and Chase Farm Hospitals NHS Trust; North Middlesex University HospitalCompletedBronchogenic CarcinomaUnited Kingdom
-
Ceska Lekarska Spolecnost Jana Evangelisty Purkyne...OAKS Consulting s.r.o.Recruiting
-
Amsterdam UMC, location VUmcGlaxoSmithKline; The Netherlands Cancer InstituteCompleted
-
Mohamed Abdel Bary Ahmed IbrahimCompletedNon Small Cell Lung Cancer | Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Bronchogenic Cancer
-
University Hospital, GrenobleUnknownImage-Guided Biopsy - Carcinoma, Bronchogenic / Diagnosis- Outpatients
-
University Hospital, LimogesGroupe Français de Pneumologie Cancérologie (GFPC)CompletedNon Small Cell Lung CarcinomaFrance
-
Latin American Cooperative Oncology GroupConselho Nacional de Desenvolvimento Científico e Tecnológico; Instituto do...CompletedNon-small Cell Lung CarcinomaBrazil
-
Spectrum Pharmaceuticals, IncWithdrawnNon-Small-Cell Lung CarcinomaUnited States, Russian Federation
-
Ontario Clinical Oncology Group (OCOG)Ontario Ministry of Health and Long Term CareCompletedPositron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)Non-Small-Cell Lung CarcinomaCanada
-
Genzyme, a Sanofi CompanyCompleted
Clinical Trials on Lucanix
-
NovaRx CorporationNo longer availableNon-small Cell Lung CancerUnited States
-
NovaRx CorporationCompletedLung Neoplasm | Carcinoma Non-small Cell Lung Cancer Stage IIIA | Carcinoma Non-small Cell Lung Cancer Stage IIIB | Carcinoma Non-small Cell Lung Cancer Stage IVUnited States, Hungary, United Kingdom, Netherlands, Canada, India, Poland, Serbia